Orforglipron 0.5mg x 25 tablets
Orforglipron is an orally bioavailable, non-peptide small-molecule GLP-1 receptor agonist developed by Eli Lilly (LY3502970). Unlike peptide-based GLP-1 agents, it is a synthetic small molecule that activates the GLP-1 receptor without an injectable format or an absorption enhancer. Supplied strictly for in-vitro research and laboratory use only.
Select Option
2+ save 5% · 5+ save 10% · 10+ save 20%
Out of Stock
Notify me when back in stock
We'll email you the moment Orforglipron is available.
- Free Priority shipping on US orders over $100
- Ships same day on orders before 2 PM MST
- Discreet, unmarked packaging
- Third-party tested to a 99%+ purity standard
Mechanism of Action
Orforglipron is a non-peptide small-molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor. It activates the receptor through a small-molecule binding mode distinct from peptide agonists and, unlike oral semaglutide, requires no permeation/absorption enhancer. It is a GLP-1-only agent, distinct from tirzepatide, a dual GIP/GLP-1 peptide.
Properties
Storage
Store at room temperature in a cool, dry place. Protect from moisture.
Shipping & Delivery
- Same-day dispatch on orders placed before 2 PM MST (Arizona — no daylight saving).
- US shipping from $5. Free Priority on orders $100+ (before discounts).
- Plain, unmarked packaging — no branding or product names on the outside.
- Ships to all 50 states, DC, Puerto Rico & the U.S. Virgin Islands; tracking emailed on every order.
Quality & Testing
- Independently tested by accredited third-party laboratories.
- Held to a 99%+ purity standard.
- USA-based; dispatched from Phoenix, Arizona.
- Supplied strictly for in-vitro laboratory research — not for human use.
Batch test records are published to each product as they are completed.
Research Applications
References & Citations
(3)Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Kawai T, Sun B, Yoshino H, et al.
Effect of food consumption on the pharmacokinetics, safety, and tolerability of once-daily orally administered orforglipron (LY3502970), a non-peptide GLP-1 receptor agonist
Ma X, Liu R, Pratt EJ, et al.
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1)
Rosenstock J, Hsia S, Nevarez Ruiz L, et al.
Research Use Only
This product is intended strictly for in-vitro research, educational, and laboratory use. Not for human consumption. The information provided is based on published research and does not constitute medical advice.